Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Newave Pharmaceutical Inc
Acerta Pharma BV
AbbVie
AbbVie
M.D. Anderson Cancer Center
Rutgers, The State University of New Jersey
AbbVie
AbbVie
AbbVie
Ohio State University Comprehensive Cancer Center
Memgen, Inc.
Fred Hutchinson Cancer Center
University of Ulm
Fred Hutchinson Cancer Center